Rallybio Corp (RLYB) · Oct 26, 2026 · Other events
$82.7M cash distribution — Estimated $13.56 per share, payable after merger approval
Rallybio’s new filing locks in an estimated $13.56-per-share cash distribution, with the Avenzo merger and shareholder vote still the gating events.
Rallybio is transitioning from a rare-disease biotech into the Avenzo-led oncology company through a reverse merger, backed by a planned $215 million financing and a pipeline of clinical-stage cancer programs. This filing mainly formalizes the cash-out mechanics, rather than changing that strategic story. The board declared an estimated $82.7 million special cash distribution, or $13.56 per share, funded by Rallybio’s pre-closing net cash.
| Item | Filing detail |
|---|---|
| Estimated total cash distribution | $82.7 million (Cash Distribution) |
| Estimated distribution per share | $13.56 (Cash Distribution) |
| Record date | November 5, 2026, subject to change (Cash Distribution) |
| Expected payment date | November 13, 2026 (Cash Distribution) |
| Expected merger closing | On or about November 6, 2026 (Cash Distribution) |
The amount is broadly consistent with what was already known. Earlier merger materials had estimated Rallybio’s net cash at approximately $82.2 million and contemplated distributing substantially all of it before or around closing, so the new information is the precise estimate, record-date mechanics, and due-bill treatment—not a surprise change in value.
The real remaining risk is execution, not the distribution decision. Payment is conditioned on the required stockholder vote scheduled for November 4, 2026, while the merger is targeted for November 6, 2026; the filing also fixes the same record date for the previously announced contingent value rights. 〔0〕 〔1〕
Bottom line: This is a confirmation and implementation notice for the already expected pre-merger cash return. It matters for timing and settlement, but does not materially alter Rallybio’s broader transition into Avenzo or remove the shareholder-approval condition.ka
Stockholder vote November 4; merger closing targeted November 6
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!